Tegoprazan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tegoprazan
DrugBank Accession Number
DB16690
Background

Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.1,2 This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.1,2 Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.2 It has also been observed to be efficacious independent of food intake.2

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 387.387
Monoisotopic: 387.13944781
Chemical Formula
C20H19F2N3O3
Synonyms
  • CJ-12420
  • IN-A001
  • K-CAB
  • LXI-15028
  • RQ-00000004
  • Tegoprazan
External IDs
  • CJ-12420
  • LXI-15028

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Tegoprazan works as a potassium-competitive acid blocker that is potent and highly selective.1,2 Its mechanism of action is different from that of the proton-pump inhibitors as this drug does not require conversion into an active form and can directly inhibit H+/K+‐ATPase in a reversible and K+‐competitive way.2 This is because it is an acid-resistant weak base with the ability to remain in the highly acidic canaliculi of gastric parietal cells.2

TargetActionsOrganism
ASodium/Potassium Transporting ATPase
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Tegoprazan.
AmphetamineTegoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmprenavirTegoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsunaprevirTegoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtazanavirTegoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
A02BC09 — Tegoprazan
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
W017G7IF4S
CAS number
942195-55-3
InChI Key
CLIQCDHNPDMGSL-HNNXBMFYSA-N
InChI
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
IUPAC Name
7-{[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]oxy}-N,N,2-trimethyl-1H-1,3-benzodiazole-5-carboxamide
SMILES
CN(C)C(=O)C1=CC(O[C@H]2CCOC3=CC(F)=CC(F)=C23)=C2NC(C)=NC2=C1

References

General References
  1. Kim DK, Lee KH, Kim SJ, Kim SJ, Lee SJ, Park CH, Kim BT, Song GS, Moon BS, Ryu SY: Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. J Pharmacol Exp Ther. 2019 Jun;369(3):318-327. doi: 10.1124/jpet.118.254904. Epub 2019 Mar 20. [Article]
  2. Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL: Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. [Article]
ChemSpider
44209499
ChEMBL
CHEMBL4297583
PDBe Ligand
8BN
PDB Entries
7w47

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHelicobacter Pylori Infection / Proton Pump Inhibitors / Vonoprazan1
4CompletedTreatmentErosive Reflux Disease2
4Not Yet RecruitingTreatmentHelicobacter Pylori Infection2
4RecruitingTreatmentGastro-esophageal Reflux Disease (GERD)1
4RecruitingTreatmentHelicobacter Pylori-positive With Functional Dyspepsia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral50.000 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0453 mg/mLALOGPS
logP2.91ALOGPS
logP2.32Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)11.37Chemaxon
pKa (Strongest Basic)6.07Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area67.45 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity98.82 m3·mol-1Chemaxon
Polarizability38.71 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014r-0539000000-62df24d7c2bd6abf457f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014r-0719000000-467509b00f58aa14a333
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-4d86510ba2bc78330eaa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00xs-0933000000-96ef75fccf56a91eb861
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6s-0916000000-ea1209af3f141debdda4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-066s-2945000000-5539415411484d3464d0
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...

Components:
References
  1. Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL: Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. [Article]

Drug created at April 26, 2021 17:31 / Updated at April 30, 2021 13:08